Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the Glioblastoma Multiforme Market Size from 2025 to 2034?

In recent times, the market size for glioblastoma multiforme has witnessed robust growth. It is projected to expand from $1.59 billion in 2024 to $1.7 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.3%. This growth during the historical period is a result of the rising cases of glioblastoma multiforme, the enhancement of healthcare infrastructure, greater cognizance, wider availability of advanced treatments, and an increase in the aging population.

In the forthcoming years, the market size for glioblastoma multiforme is predicted to experience robust growth. It is projected to reach$2.27 billion by 2029 with a 7.5% compound annual growth rate (CAGR). The anticipated growth for this period can be ascribed to rising instances of nervous system and brain cancers, increased acceptance of surgical methodologies, enhanced awareness, disease early diagnosis, and a surge in R&D endeavors. Key trends for this period comprises progress in medical technology, breakthroughs in imaging techniques, individualized medicine, AI deployment in diagnosis, and advancements in technology and science.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

Which Factors and External Forces Are Driving Demand in the Glioblastoma Multiforme Market?

Increasing cases of brain malfunctions are set to propel the glioblastoma multiforme market in the future. Brain disorders cause disruptions in the structural and functional aspects of the brain, resulting in cognitive, emotional, or physical deficiencies. The escalation in brain disorder instances attributes to elements like aging population, lengthier life spans, lifestyle factors, and enhanced diagnostic facilities. Comprehending these disorders is crucial for progressing glioblastoma multiforme (GBM) research, thereby enabling earlier detection, inventive cures, and improved patient results. Examining these neurological conditions enables scientists to identify the genetic and molecular connections leading to GBM. For example, as per Dementia Australia, a non-profit organization from Australia, around 433,300 Australians were reported to have dementia in February 2025. This figure is projected to reach 812,500 by 2054. Plus, younger-onset dementia impacted approximately 29,000 individuals in 2025, with future estimates suggesting a rise to 41,000 by 2054. Thus, the escalating instances of brain disorders will foster the expansion of the glioblastoma multiforme market.

Which Segments in the Glioblastoma Multiforme Offer the Most Growth?

The glioblastoma multiformemarket covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents; Temozolomide; Carmustine; Lomustine; Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI); Computed Tomography Scan (CT Scan); Biopsy; Other Diagnostic Tools

3) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Immunotherapy; Tumor Treating Field Therapy; Other Treatment Types

4) By End-User: Hospitals; Cancer Research Institutes; Ambulatory Surgical Centers; Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents; Platinum-Based Agents; Antimetabolites

2) By Temozolomide: Branded (Temodar); Generic Temozolomide

3) By Carmustine: Injectable Carmustine; Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine); Generic Lomustine

5) By Other Drug Classes: Targeted Therapy; Immunotherapy; Tumor-Treating Fields (TTF) Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21191&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Glioblastoma Multiforme Market?# Market?

North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theGlioblastoma Multiforme Market’s Growth?

Leading businesses in the glioblastoma multiforme market are striving to create advanced treatments, such as CAR T-cell therapies, to meet the pressing medical demands for severe cancer forms. CAR T-cell therapies, an immunotherapy variation, enhances the patient’s T-cells’ capacity to effectively locate and terminate cancer cells. As an example, Chimeric Therapeutics Limited, a biotechnology firm located in Australia, initiated a Phase IB clinical study of CHM 1101 (CLXT CAR T) therapy in June 2023. This therapy is for recurrent or progressive glioblastoma multiforme (GBM). Multiple centers executed the study with a goal to assess the safety and efficiency of the therapy while deciding the suitable dosage for Phase 2. The preliminary results of Phase 1a implied disease consistency and the study will factor this into the further development stages. The company anticipates using the research data for designing a registration trial and pursuing regulatory insights.

View the full report here:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

What Are the Key Elements That Define the Glioblastoma Multiforme Market?

Glioblastoma multiforme (GBM) is an aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21191

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model